Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group.
Saburi M, Oshima K, Takano K, Inoue Y, Harada K, Uchida N, Fukuda T, Doki N, Ikegame K, Matsuo Y, Katayama Y, Ozawa Y, Matsuoka KI, Kawakita T, Mori Y, Ara T, Nakamae H, Kimura T, Kanda Y, Atsuta Y, Ogata M; Transplant Complications Working Group of the Japanese Society for Transplantation and Cellular Therapy. Saburi M, et al. Among authors: matsuoka ki. Ann Hematol. 2023 Sep;102(9):2507-2516. doi: 10.1007/s00277-023-05320-4. Epub 2023 Jun 20. Ann Hematol. 2023. PMID: 37338625
Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.
Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M, Yano T, Asakura S, Sunami K, Tabayashi T, Miyata A, Matsuoka KI, Shinagawa K, Ikeda K, Matsuo K, Tanimoto M; West-Japan Hematology and Oncology Group (West-JHOG). Hiramatsu Y, et al. Among authors: matsuoka ki. Int J Hematol. 2008 Dec;88(5):588-595. doi: 10.1007/s12185-008-0196-y. Epub 2008 Nov 29. Int J Hematol. 2008. PMID: 19039629 Clinical Trial.
Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, Otsuka E, Henzan H, Kato K, Tomoyose T, Yamamoto H, Kurosawa S, Matsuoka K, Yamaguchi T, Fukuda T. Fuji S, et al. J Clin Oncol. 2016 Oct 1;34(28):3426-33. doi: 10.1200/JCO.2016.67.8250. Epub 2016 Aug 9. J Clin Oncol. 2016. PMID: 27507878
Impact of a Low CD34+ Cell Dose on Allogeneic Peripheral Blood Stem Cell Transplantation.
Yamamoto C, Ogawa H, Fukuda T, Igarashi A, Okumura H, Uchida N, Hidaka M, Nakamae H, Matsuoka KI, Eto T, Ichinohe T, Atsuta Y, Kanda Y. Yamamoto C, et al. Among authors: matsuoka ki. Biol Blood Marrow Transplant. 2018 Apr;24(4):708-716. doi: 10.1016/j.bbmt.2017.10.043. Epub 2017 Nov 28. Biol Blood Marrow Transplant. 2018. PMID: 29196077 Free article. Clinical Trial.
Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan.
Itonaga H, Aoki K, Aoki J, Ishikawa T, Ishiyama K, Uchida N, Sakura T, Ohashi K, Kurokawa M, Ozawa Y, Matsuoka KI, Nakamura Y, Kimura F, Iwato K, Nawa Y, Hirokawa M, Kato K, Ichinohe T, Atsuta Y, Miyazaki Y. Itonaga H, et al. Among authors: matsuoka ki. Biol Blood Marrow Transplant. 2018 Apr;24(4):840-848. doi: 10.1016/j.bbmt.2017.11.016. Epub 2017 Nov 28. Biol Blood Marrow Transplant. 2018. PMID: 29196081 Free article. Clinical Trial.
Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation.
Ikegawa S, Matsuoka KI, Inomata T, Ikeda N, Sugiura H, Kuroi T, Asano T, Yoshida S, Nishimori H, Fujii N, Kondo E, Maeda Y, Tanimoto M. Ikegawa S, et al. Among authors: matsuoka ki. Int J Hematol. 2018 May;107(5):568-577. doi: 10.1007/s12185-017-2398-7. Epub 2018 Jan 4. Int J Hematol. 2018. PMID: 29299798
Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y. Ishikawa J, et al. Among authors: matsuoka ki. Int J Hematol. 2018 May;107(5):535-540. doi: 10.1007/s12185-018-2401-y. Epub 2018 Jan 23. Int J Hematol. 2018. PMID: 29362980 Clinical Trial.
153 results